汇宇制药(688553) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥239,052,524.64, a decrease of 1.46% compared to ¥242,604,188.27 in the same period last year[3]. - The net profit attributable to shareholders was -¥25,626,485.30, representing a decline of 155.19% from ¥46,435,905.16 year-on-year[3]. - Net profit for Q1 2025 was a loss of ¥26,685,549.35, compared to a profit of ¥44,879,334.61 in Q1 2024[15]. - The total comprehensive income for Q1 2025 was a loss of ¥27,288,527.71, compared to a profit of ¥44,948,732.88 in Q1 2024[16]. - The basic and diluted earnings per share were both -¥0.06, a decline of 154.55% from ¥0.11 in the same period last year[3]. - The company reported a basic and diluted earnings per share of -¥0.06 for Q1 2025, down from ¥0.11 in Q1 2024[16]. Cash Flow - The net cash flow from operating activities decreased by 80.94%, amounting to ¥2,561,923.01 compared to ¥13,438,049.99 in the previous year[3]. - The net cash flow from operating activities for Q1 2025 was ¥2,561,923.01, a significant decrease from ¥13,438,049.99 in Q1 2024[18]. - Cash flow from investing activities in Q1 2025 showed a net outflow of ¥187,495,816.08, compared to a net inflow of ¥39,578,048.79 in Q1 2024[19]. - Cash flow from financing activities resulted in a net outflow of ¥57,582,467.51 in Q1 2025, contrasting with a net inflow of ¥131,884,679.85 in Q1 2024[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,949,444,136.80, down 4.19% from ¥5,165,626,758.56 at the end of the previous year[4]. - The company's current assets totaled CNY 3,151,505,632.34, down from CNY 3,344,348,217.96, indicating a decrease of about 5.77%[11]. - Cash and cash equivalents decreased to CNY 1,981,653,478.45 from CNY 2,328,244,429.04, representing a decline of approximately 14.92%[11]. - The company's total liabilities were CNY 1,003,352,262.73, down from CNY 1,192,246,356.78, showing a reduction of about 15.85%[13]. - The total equity attributable to shareholders decreased to CNY 3,952,814,982.22 from CNY 3,979,044,445.88, reflecting a decline of approximately 0.66%[13]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,434[8]. - The largest shareholder, Ding Zhao, holds 26.93% of the shares, totaling 114,066,766 shares[8]. - Huang Qianyi, the second-largest shareholder, holds 6.43% of the shares, with 27,219,439 shares, of which 27,090,000 shares are pledged[8]. Research and Development - Research and development expenses totaled ¥67,083,832.82, accounting for 28.06% of operating revenue, an increase of 0.34 percentage points from the previous year[4]. - Research and development expenses for Q1 2025 were ¥61,856,632.31, a decrease of 5.0% from ¥65,507,169.10 in Q1 2024[15]. - The company's development expenditure increased to CNY 30,930,605.69 from CNY 25,703,405.18, representing an increase of approximately 20.00%[12]. Inventory and Accounts Payable - The company's inventory increased to CNY 202,748,808.40 from CNY 159,919,087.79, marking an increase of about 26.79%[11]. - The company's accounts payable decreased to CNY 145,309,958.59 from CNY 193,038,394.03, indicating a decline of approximately 24.69%[12]. Other Financial Metrics - The weighted average return on net assets was -0.65%, a decrease of 1.86 percentage points compared to 1.21% in the previous year[3]. - The company reported a decrease in retained earnings to CNY 927,980,229.38 from CNY 953,606,714.68, reflecting a decline of about 2.70%[13].